Dr. Labelle is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5841 S Maryland Ave
Chicago, IL 60637Phone+1 888-824-0200Fax+1 773-834-1329
Education & Training
- Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 2006 - 2009
- Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 2003 - 2006
- Medical College of WisconsinClass of 2003
Certifications & Licensure
- IL State Medical License 2012 - 2026
- MA State Medical License 2007 - 2014
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Venetoclax Induces BCL-2-Dependent Treg to TH17 Plasticity to Enhance the Antitumor Efficacy of Anti-PD-1 Checkpoint Blockade.Rosy Liao, Jocelyn Y Hsu, Nada S Aboelella, Joshua A McKeever, Anika T Thomas-Toth
Cancer Immunology Research. 2024-08-01 - FLT3 inhibitor maintenance after allogeneic stem cell transplantation in-mutated acute myeloid leukemia (AML) patients.Gong He, Erika Belmont, Theodore Karrison, Wendy Stock, James L LaBelle
Annals of Translational Medicine. 2024-06-10 - Combination fedratinib and venetoclax has activity against human B-ALL with high FLT3 expression.Sean P Rinella, Haley C Bell, Nicholas J Hess, Nguyet-Minh Hoang, Thao Trang Nguyen
Biorxiv. 2024-05-06
Press Mentions
- South Side Resident Takes Part in Rare Sickle Cell Disease Clinical Trial Through UChicago MedicineSeptember 8th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: